Price Chart

Key Stats

Customize
Expense Ratio Discount or Premium to NAV Total Assets Under Management 30-Day Average Daily Volume
0.44% 0.02% 9.010B 2.045M
Dividend Yield Turnover Ratio 1 Year Fund Level Flows Max Drawdown (All)
0.22% 46.00% 236.69M Upgrade

Basic Info

Investment Strategy
The investment seeks to track the investment results of the ICE Biotechnology Index composed of U.S.-listed equities in the biotechnology sector. The fund generally will invest at least 80% of its assets in the component securities of its index and in investments that have economic characteristics that are substantially identical to the component securities of its index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.
General
Security Type Exchange-Traded Fund
Equity Style Mid Cap/Blend
Fixed Income Style --
Broad Asset Class Sector Equity
Broad Category Equity
Category Name Health
Category Index S&P 1500 Health Care TR
Global Category Name Healthcare Sector Equity
YCharts Categorization Healthcare Equity
YCharts Benchmark S&P 1500 Health Care (Sector) Total Return (^SP15HCSTR)
Prospectus Objective Specialty - Technology
Fund Owner Firm Name iShares
Prospectus Benchmark Index
ICE Biotechnology TR USD 100.0%
Broad Asset Class Benchmark Index
^MSWNTR 100.0%
Manager Tenure
Greg Savage 14.84 yrs
Jennifer Hsui 10.26 yrs
Amy Whitelaw 4.25 yrs
Paul Whitehead 0.83 yrs

Net Fund Flows Versus Category

View Net Fund Flows. Upgrade now.
1M
3M
6M
YTD
1Y
3Y
5Y
10Y
 
80.00B
60.00B
40.00B
20.00B
0
-20.00B
1 Month
% Rank: --
-- Category Low
-- Category High
1 Year
% Rank: 7
236.69M
-3.207B Category Low
8.763B Category High
3 Months
% Rank: --
-- Category Low
-- Category High
3 Years
% Rank: --
-- Category Low
-- Category High
6 Months
% Rank: --
-- Category Low
-- Category High
5 Years
% Rank: --
-- Category Low
-- Category High
YTD
% Rank: --
-- Category Low
-- Category High
10 Years
% Rank: --
-- Category Low
-- Category High
As of November 30, 2022

Performance Versus Category

 
20%
15%
10%
5%
0
View Category Returns. Upgrade now.
Name
1M
3M
YTD
1Y
3Y
5Y
10Y
15Y
Total Return (Price)
--
--
--
--
--
--
--
--
Total Return (NAV)
--
--
--
--
--
--
--
--
Category Rtn. (NAV)
--
--
--
--
--
--
--
--
% Rank in Cat (NAV)
--
--
--
--
--
--
--
--
As of December 02, 2022. Returns for periods of 1 year and above are annualized.

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
11.56%
-21.41%
21.08%
-9.53%
25.21%
26.01%
0.95%
-9.06%
-0.87%
7.51%
22.40%
-8.71%
27.67%
15.90%
21.82%
-14.12%
0.27%
-5.21%
21.82%
-1.33%
22.26%
28.00%
15.20%
-10.64%
-3.33%
15.39%
35.82%
2.72%
38.65%
54.19%
18.19%
-25.92%
1.64%
-23.20%
12.05%
-15.32%
25.62%
14.68%
-10.53%
-4.47%
-0.95%
21.24%
32.99%
-4.58%
39.34%
6.19%
2.31%
-2.72%
As of December 02, 2022.

Fundamentals

General
Distribution Yield Upgrade
Dividend Yield TTM (12-2-22) 0.22%
30-Day SEC Yield (10-31-22) Upgrade
7-Day SEC Yield --
Number of Holdings Upgrade
Stock
Weighted Average PE Ratio 14.25
Weighted Average Price to Sales Ratio Upgrade
Weighted Average Price to Book Ratio Upgrade
Weighted Median ROE Upgrade
Weighted Median ROA Upgrade
Forecasted Dividend Yield Upgrade
Forecasted PE Ratio Upgrade
Forecasted Price to Sales Ratio Upgrade
Forecasted Price to Book Ratio Upgrade
As of November 25, 2022

Growth Estimates

Forecasted 5 Yr Earnings Growth Upgrade
Forecasted Book Value Growth Upgrade
Forecasted Cash Flow Growth Upgrade
Forecasted Earnings Growth Upgrade
Forecasted Revenue Growth Upgrade
As of November 25, 2022

Asset Allocation

As of November 28, 2022.
Type % Net % Long % Short
Cash 0.13% Upgrade Upgrade
Stock 99.87% Upgrade Upgrade
Bond 0.00% Upgrade Upgrade
Convertible 0.00% Upgrade Upgrade
Preferred 0.00% Upgrade Upgrade
Other 0.00% Upgrade Upgrade

Top 10 Holdings

Name % Weight Price % Change
Gilead Sciences Inc 9.84% 89.03 1.29%
Amgen Inc 8.73% 285.51 -0.15%
Vertex Pharmaceuticals Inc 7.42% 321.37 0.19%
Regeneron Pharmaceuticals Inc 7.01% 766.39 0.68%
Moderna Inc 5.45% 182.35 0.48%
Biogen Inc 3.89% 298.90 -0.98%
IQVIA Holdings Inc 3.66% 217.73 -1.28%
Illumina Inc 3.13% 218.76 -0.95%
Mettler-Toledo International Inc 2.94% 1486.10 -0.28%
BioNTech SE ADR 2.81% 169.74 0.16%

Basic Info

Investment Strategy
The investment seeks to track the investment results of the ICE Biotechnology Index composed of U.S.-listed equities in the biotechnology sector. The fund generally will invest at least 80% of its assets in the component securities of its index and in investments that have economic characteristics that are substantially identical to the component securities of its index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.
General
Security Type Exchange-Traded Fund
Equity Style Mid Cap/Blend
Fixed Income Style --
Broad Asset Class Sector Equity
Broad Category Equity
Category Name Health
Category Index S&P 1500 Health Care TR
Global Category Name Healthcare Sector Equity
YCharts Categorization Healthcare Equity
YCharts Benchmark S&P 1500 Health Care (Sector) Total Return (^SP15HCSTR)
Prospectus Objective Specialty - Technology
Fund Owner Firm Name iShares
Prospectus Benchmark Index
ICE Biotechnology TR USD 100.0%
Broad Asset Class Benchmark Index
^MSWNTR 100.0%
Manager Tenure
Greg Savage 14.84 yrs
Jennifer Hsui 10.26 yrs
Amy Whitelaw 4.25 yrs
Paul Whitehead 0.83 yrs

Fundamentals

General
Distribution Yield Upgrade
Dividend Yield TTM (12-2-22) 0.22%
30-Day SEC Yield (10-31-22) Upgrade
7-Day SEC Yield --
Number of Holdings Upgrade
Stock
Weighted Average PE Ratio 14.25
Weighted Average Price to Sales Ratio Upgrade
Weighted Average Price to Book Ratio Upgrade
Weighted Median ROE Upgrade
Weighted Median ROA Upgrade
Forecasted Dividend Yield Upgrade
Forecasted PE Ratio Upgrade
Forecasted Price to Sales Ratio Upgrade
Forecasted Price to Book Ratio Upgrade
As of November 25, 2022

Growth Estimates

Forecasted 5 Yr Earnings Growth Upgrade
Forecasted Book Value Growth Upgrade
Forecasted Cash Flow Growth Upgrade
Forecasted Earnings Growth Upgrade
Forecasted Revenue Growth Upgrade
As of November 25, 2022

Fund Details

Key Dates
Inception Date 2/5/2001
Last Annual Report Date 3/31/2022
Last Prospectus Date 8/1/2022
Attributes
Index Fund Yes
Inverse Fund No
Leveraged Fund No
Fund of Funds No
Currency Hedged Fund No
Synthetic Replication Fund No
Has Dividend Investment Plan Yes
Socially Responsible Fund No

Top Portfolio Holders

0 of 0